Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Verve Therapeutics (VERV)
NASDAQ:VERV
Verve Therapeutics (VERV) Stock Price & Analysis
468 Followers
VERV Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.59 - $21.04
Previous Close$6.73
Volume1.35M
Average Volume (3M)1.38M
Market Cap
$565.09M
Enterprise Value$32.39M
Total Cash (Recent Filing)$606.37M
Total Debt (Recent Filing)$73.67M
Price to Earnings (P/E)―
Beta2.58
Next Earnings
Aug 08, 2024EPS Estimate
-$0.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.88
Shares Outstanding83,965,493
10 Day Avg. Volume1,543,381
30 Day Avg. Volume1,375,030
Standard Deviation0.27
R-Squared0.13
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)0.74
Price to Sales (P/S)86.35
Price to Cash Flow (P/CF)-2.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.99
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.20
Forecast
1Y Price Target
$25.67Price Target Upside258.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Verve Therapeutics News
PremiumCompany Announcements
Verve Therapeutics Expands Board with Two New Members
PremiumCompany Announcements
Verve Therapeutics Announces New Chief Scientific Officer
PremiumPress Releases
Verve Therapeutics Announces Leadership Update
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe first patient has been dosed in the Heart-2 Ph1b trial.
Financial PerformanceVerve ended 1Q24 with roughly $606.4M in cash and cash equivalents, which provides a runway into late 2026.
Stock ValuationVERV stock trades below cash and could see upward momentum from any positive developments.
Bears Say
Clinical TrialsVerve to pause enrollment in the Phase 1b trial of VERVE-101 due to transient lab abnormalities.
Safety ConcernsOne patient in the 0.45 mg/kg cohort also experienced a myocardial infarction (MI) one day post-treatment deemed to be potentially related to VERVE-101 treatment.
Stock PerformanceA recent safety surprise sent the stock downward ~40%.
---
Ownership Overview
51.40% Insiders
26.27% Mutual Funds
18.20% Other Institutional Investors
4.12% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VERV FAQ
What was Verve Therapeutics’s price range in the past 12 months?
Verve Therapeutics lowest stock price was $4.58 and its highest was $21.04 in the past 12 months.
What is Verve Therapeutics’s market cap?
Currently, no data Available
When is Verve Therapeutics’s upcoming earnings report date?
Verve Therapeutics’s upcoming earnings report date is Aug 08, 2024 which is in 18 days.
How were Verve Therapeutics’s earnings last quarter?
Verve Therapeutics released its earnings results on May 08, 2024. The company reported -$0.59 earnings per share for the quarter, beating the consensus estimate of -$0.702 by $0.112.
Is Verve Therapeutics overvalued?
According to Wall Street analysts Verve Therapeutics’s price is currently Undervalued.
Does Verve Therapeutics pay dividends?
Verve Therapeutics does not currently pay dividends.
What is Verve Therapeutics’s EPS estimate?
Verve Therapeutics’s EPS estimate is -$0.68.
How many shares outstanding does Verve Therapeutics have?
Verve Therapeutics has 83,965,490 shares outstanding.
What happened to Verve Therapeutics’s price movement after its last earnings report?
Verve Therapeutics reported an EPS of -$0.59 in its last earnings report, beating expectations of -$0.702. Following the earnings report the stock price went down -1.299%.
Which hedge fund is a major shareholder of Verve Therapeutics?
Among the largest hedge funds holding Verve Therapeutics’s share is ARK Investment Management LLC. It holds Verve Therapeutics’s shares valued at 80M.
---
Verve Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.67 (258.52% Upside)
$25.67 (258.52% Upside)
Blogger Sentiment
Bullish
VERV Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 958.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $475.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-66.78%
12-Months-Change
Fundamentals
Return on Equity
-36.03%
Trailing 12-Months
Asset Growth
15.45%
Trailing 12-Months
Company Description
Verve Therapeutics
Verve Therapeutics Inc is a genetic medicines company pioneering the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. Its initial programs focus on PCSK9 and ANGPTL3, two genes that regulate levels of blood lipids. The company is developing these gene-editing treatments for patients with familial hypercholesterolemia, a genetic disease that causes life-long severely elevated blood cholesterol.
---
VERV Stock 12 Month Forecast
Average Price Target
$25.67
▲(258.52% Upside)
Technical Analysis
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Editas Medicine
―
Voyager Therapeutics
―
Best Analysts Covering VERV
1 Year
1 Year Success Rate
1/6 ratings generated profit
1 Year Average Return
-31.28%
reiterated a buy rating 2 months ago
Copying Cory Jubinville, PhD's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -31.28% per trade.
---